



<https://www.medpagetoday.com/infectiousdisease/covid19/120915>

Key Takeaways

- Two multicenter trials found no change in hospitalization and death rates when antiviral nirmatrelvir-ritonavir (Paxlovid) was given to COVID-19 patients already mostly vaccinated.
- However, nirmatrelvir-ritonavir was linked to more early sustained recovery when taken within the first 5 days of illness in both trials.
- Additionally, there was evidence of more nirmatrelvir-ritonavir recipients reaching a viral load below detection level at day 5 following treatment.